HTFL · Heartflow, Inc. · Stock research

Current Thesis

The leg being bought is a single-quarter re-rating of AI coronary diagnostics from "growth medtech" to "category compounder with 83% gross margin." On 2026-08-13 Heartflow reported Q2 2026 revenue of $64.1M, +48% YoY, and raised full-year 2026 revenue guidance to $246–250M (40–42% YoY) from $228–232M — a range that sits entirely above the $230.073M consensus Benzinga logged going into the print. Six sell-side desks moved targets the following session. Price closed 2026-08-14 at $42.08, a 52-week high, with RSI(14) at 93.4 and a three-month return of +48.6%. The business evidence is fresh and dated; the entry is at the extreme end of the move, and no company-confirmed event sits inside the next 30 days.

Life-cycle: ACCELERATING. What dates it: the 2026-08-13 print, the +26.5% intraday move Benzinga logged on 2026-08-14, and six target revisions inside one session (JP Morgan, Piper Sandler, Stifel, Canaccord to $45; Morgan Stanley $40; Wells Fargo $39). New attention arrived on a specific day, not gradually. The counter-observable is already visible: at $42.08 the stock trades above two of those six published targets.

Bullish and bearish views on Heartflow, Inc.

The model's bull view on Heartflow, Inc. (HTFL), in brief: Q2 2026 revenue $64.1M, +48% YoY (press release, 2026-08-13); U.S. revenue $59.6M, +51% YoY. The bear view: Operating expenses were $71.1M in Q2, 111% of revenue (2026-08-13 release). Both cases follow in full.

Bull Case

• Q2 2026 revenue $64.1M, +48% YoY (press release, 2026-08-13); U.S. revenue $59.6M, +51% YoY. Growth is domestic and accelerating, not FX or one-off.
• FY2026 guide lifted to $246–250M from $228–232M in a single step (2026-08-13). Guidance raises of that size mid-year are the mechanism through which a small-cap medtech re-rates.
• Plaque revenue $7.8M in Q2, roughly $4M above management's own expectation, with the FY Plaque outlook raised to $29–31M (Seeking Alpha, 2026-08-13). A second product line inflecting turns a one-product story into a platform story — the actual narrative leg.
• GAAP gross margin 83.0%, non-GAAP 83.3% (Q2 2026 release). Software-like unit economics on a reimbursed medical service; FY non-GAAP gross margin guided to ~82%.
• Loss narrowing faster than modelled: non-GAAP net loss $5.8M, or $(0.07)/sh, against the $(0.13) consensus Benzinga carried; adjusted EBITDA $(6.7)M.
• $246.8M cash, equivalents and investments at 2026-06-30, against a Q2 adjusted EBITDA loss of $6.7M. Funding is not the near-term constraint.

Bear Case

• Operating expenses were $71.1M in Q2, 111% of revenue (2026-08-13 release). This is not yet a profitable business; the whole valuation rests on the guide holding.
• Price is through part of the sell-side range. Wells Fargo's $39 and Morgan Stanley's $40 (both 2026-08-14, the latter Equal-Weight) sit below the 2026-08-14 close of $42.08. The $45 cluster is a single-digit percentage away.
• Plaque is early and lumpy. A $4M beat against plan in one quarter is as easily a timing pull-forward as a run-rate. The $29–31M FY Plaque outlook has one more quarter to prove itself.
• Insider supply is ongoing. SEC EDGAR (CIK 0001464521) lists a run of Heartflow Form 4 filings through 2026-08-10, including officer dispositions executed under Rule 10b5-1 plans. Supply into strength from a recently listed cap table is a structural feature, not an event.
• Reimbursement is a policy variable, not a company variable. FFRCT economics sit inside the CMS rulemaking cycle; the CY2027 physician fee schedule and OPPS final rules land in the November window, outside anything management controls.
• Data hygiene: several wire summaries on 2026-08-13 carried Q2 revenue as $53.190M against a $56.642M estimate. The company release states $64.1M. Screens and quant feeds keyed to the wire number will read this name wrong.

Setup & Price Structure

The 2026-08-14 close of $42.08 is the 52-week high — 0.0% below it — reached on a gap that Benzinga measured at +26.5% intraday. RSI(14) at 93.4 is a reading that occurs in the first days of a re-rating and in the last days of one; it does not distinguish between them. Three-month price change: +48.6%.

Structurally, the entire move is one unfilled gap sitting on top of a pre-print range. There is no base above the gap and no test of it yet. The relevant question for the next month is whether the gap gets defended on the first retest or filled. Crowding observables, stated plainly: six target revisions on one day; the last close above two of six published targets; a completed earnings event that removes the next scheduled news for roughly three months; and a continuing Form 4 cadence. None of those is a verdict — together they describe a tape where the marginal new buyer is arriving after the information, into a name with no dated catalyst to absorb the flow.

Catalyst Calendar (next 30 days)

• No company-confirmed dated event between 2026-08-16 and 2026-09-15. This is the finding, not an omission: Q2 was reported 2026-08-13 and the reporting cadence (Q1 on 2026-05-14, Q2 on 2026-08-13) puts the next print outside the window.
• ~2026-11-12 (est.) — Q3 2026 results. First test of the $246–250M FY2026 range and of whether Plaque compounds off the $7.8M Q2 quarter toward the $29–31M FY outlook.
• Early November 2026 (est.) — CMS CY2027 OPPS and physician fee schedule final rules. The recurring policy checkpoint for reimbursed diagnostic services.
• Within the window, price action is flow-driven. Any dated news would have to come from outside the reporting calendar — a registration statement, a coverage decision, a partnership.

What Would Change Our Mind

The structure that has to hold is the 2026-08-14 gap. The whole re-rating happened in one session; if that session's range is given back, the market has decided the $246–250M guide was already in the price at $42.08. A weekly close below $34 retraces the print move in full and puts the stock back inside its pre-Q2 range — that is the gradeable break.

Second, a fundamental reversal at the ~2026-11-12 Q3 print: any trim to the $246–250M FY2026 range, or Plaque revenue below the $7.8M booked in Q2, would break the platform-inflection leg specifically rather than just the price.

Third, a supply event. An S-3 or follow-on into strength, with $246.8M already on the balance sheet at 2026-06-30, would say management reads its own multiple as a currency — an observable that changes the risk of holding a name trading at its high.

Fourth, the theme flipping to SATURATED: if the six 2026-08-14 target revisions are the last ones and the $45 cluster stops moving through Q3, the fresh bid is gone and what remains is a name priced above half of its published targets.

Correlation Notes

• Trades with the unprofitable U.S. medtech-growth cohort — adjusted EBITDA of $(6.7)M in Q2 makes the multiple duration-sensitive, so long-end rate moves hit it before the fundamentals do.
• The upstream volume driver is coronary CTA scan volumes, which tie to hospital imaging capex and the installed CT base (GE HealthCare, Siemens Healthineers, Canon Medical). A slowdown in scanner placements is a leading indicator for case growth two to four quarters out.
• Shared factor with the broader diagnostics complex: the CMS rulemaking cycle. Reimbursement headlines move the group together regardless of company-specific results.
• Idiosyncratic risk dominates near term. The 2026-08-14 move was company-specific; sector beta explains little of the +48.6% three-month return.